Timing of Familial Breast Cancer in Sisters

Size: px
Start display at page:

Download "Timing of Familial Breast Cancer in Sisters"

Transcription

1 ARTICLE Timing of Familial Breast Cancer in Sisters Paola Rebora, Kamila Czene, Marie Reilly Background Methods Results Conclusions Women who have had a first-degree relative diagnosed with breast cancer (ie, a positive family history) have a rate of breast cancer that is approximately twice that of all women their age, but it is unclear how they should perceive this risk at different ages or if they should be considered at higher risk for the remainder of their lifetime. We used Swedish population based data to assess the risk of breast cancer in sisters of women diagnosed with breast cancer and in sisters of unaffected women from 1958 through Poisson models were used to express the rate of breast cancer as a function of current age, whether a woman had an affected sister, time since the first diagnosis in the family, and family size (number of sisters). The effect of the age of the index case (the first sister diagnosed in the family) at diagnosis and whether her at-risk sisters had achieved this age were examined in stratified analyses. Incidence rate ratios of breast cancer in exposed compared with unexposed sisters were calculated with 95% confidence intervals. All estimates were adjusted for calendar time. Sisters of breast cancer patients had higher breast cancer incidence than unexposed sisters at all ages. The association of exposure (ie, a diagnosis of breast cancer in a sister) with the risk of breast cancer was most pronounced in young women (age 20 39; incidence rate ratio = 6.64, 95% confidence interval = 4.66 to 9.48), and the relative risk decreased to approximately 2 in women older than 50 years. The risk associated with having a sister diagnosed with breast cancer was not modified substantially by the age of the index case at diagnosis ( 45 years vs >45 years). The risk was similar for women who were approaching the age at which the first sister was diagnosed in their family and those who had already attained it. The incidence rate ratio of breast cancer in exposed sisters compared with unexposed sisters was constant over time for all age categories of at-risk women. Women who have a sister diagnosed with breast cancer have an increased risk of breast cancer throughout much of their lifetimes. J Natl Cancer Inst 2008;100: There is a large volume of published work on the risk of breast cancer in women with a family history, with first-degree relatives of breast cancer patients having a risk approximately twice that of all women their age in the population ( 1, 2 ). As a result, women are perceived to be at increased risk from the time of diagnosis in a first-degree relative, but less is known about how they should assess this risk at different ages. Some studies have shown that the familial breast cancer risk in first-degree relatives of breast cancer patients decreases with increasing age at diagnosis of the breast cancer patient and age of the relative ( 3, 4 ). The association of young age at onset of breast cancer with familial risk has been previously emphasized ( 5 ), but it is still unclear whether the age at onset is genetically determined ( 6, 7 ). In addition to age, there is another timescale that may be important for counseling purposes, namely, the time since the index (ie, first) diagnosis in a first-degree relative. Bermejo et al. ( 8 ) noted that just after the first diagnosis of breast cancer in a family, increased surveillance of the other at-risk family members can lead to earlier detection of cancers, thus biasing the estimate of the risk of familial cancers. The contributions to familial breast cancer risk of the age of the at-risk woman, the age at diagnosis of the first case in her family, and the time since the index diagnosis are still unclear. To our knowledge, no work has been undertaken to investigate whether women in affected families should be considered at higher risk for the rest of their lifetimes or whether those who have survived free of breast cancer for a given time after a diagnosis in a relative have a risk similar to that of women their age in the general population. The main aim of our study was to clarify the associations of breast cancer risk with the current age of the woman at risk, age at diagnosis of her index sister (the first sister to be diagnosed in the Affiliation of authors: Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Box 281, Stockholm, Sweden. Correspondence to: Marie Reilly, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Box 281, Stockholm, Sweden ( marie.reilly@ki.se ). See Funding and Notes following References. DOI: /jnci/djn146 The Author Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org. jnci.oxfordjournals.org JNCI Articles 721

2 CONTEXT AND CAVEATS Prior knowledge Having a sister diagnosed with breast cancer increases a woman s risk of breast cancer, but how this increase in risk depends on the time elapsed since the sister s diagnosis, the age of the at-risk sister, and other factors was unclear. Study design Using data on birth dates and parentage that were linked to a national cancer register, Poisson models were constructed to determine the risk of breast cancer associated with having a sister diagnosed with the disease and how it varied according to the age of the at-risk woman, the time elapsed since the diagnosis of her sister, and other parameters. Contribution The increased risk of breast cancer associated with having a sister diagnosed with the disease was most pronounced in younger women, and for all women the increased risk was constant over the time elapsed since the sister s diagnosis. Implications Women with a sister diagnosed with breast cancer remain at increased risk for much of their lifetime. Limitations The study could not assess the risk associated with having a sister diagnosed with breast cancer in women older than 70 years. family), and time since the index diagnosis. Our goal was to better understand the timing of familial breast cancer. Methods Study Design We analyzed the timing of familial breast cancer in Swedish sisters in terms of both absolute and relative risks. We estimated the absolute risk of breast cancer as a function of age adjusting for calendar year in exposed (ie, a sister had been diagnosed with breast cancer) and unexposed women. We then proceeded to study the risk in exposed women relative to the risk in unexposed women, stratifying by age to accommodate age-specific differences in incidence rates. Third, we investigated whether the risk in exposed women (relative to the risk in unexposed women) changed with time after the diagnosis of the index case. Finally, to combine the time elements, we stratified at-risk sisters by their current age and calculated the relative risk for different time intervals after exposure. Data Sources Statistics Sweden maintains a Multi-Generation Register that registers children born in Sweden since 1932 along with their biologic or adopted parents. Children who died before 1960 are not included. Using the unique national registration numbers, we linked the individuals in this register to the Swedish Cancer Register to obtain all malignancies that were recorded between 1958 and Cancers were coded according to the seventh revision of the International Classification of Diseases ( ICD-7 ), and the information in the cancer register enables first and subsequent primary cancers and cancers in situ to be identified. Due to the inclusion criteria of the Multi-Generation Register, we could not identify any sisters born before Furthermore, approximately 40% of offspring who died before 1991 did not have links to both parents, so we could not identify their full siblings ( 9 ). By linking to the nationwide census, death notification, and migration databases, we obtained the vital status and migration information necessary for censoring and some additional demographic information. The study was approved by the Stockholm regional ethics committee. Study Design and Study Subjects We identified all women born in Sweden between 1932 and 2001 and with at least one sister recorded in the Multi- Generation Register ( individuals in families). After the exclusion of 4063 women (7 who emigrated before 1958, 2302 who were censored in the same month as their birth, and 1754 for whom there was an inconsistent registration of first immigration), the remaining women included 2348 who no longer had any sister in the dataset. Thus, the final dataset for analysis included women from families who were followed from the start of the Cancer Register ( January 1, 1958) or from their birth until they experienced a diagnosis of malignant breast cancer ( ICD-7 code 170) or until December 31, Women were censored if they died (1%), emigrated (4%), were diagnosed with another cancer (2%), or reached the end of the study on December 31, 2001 (92%). The first breast cancer diagnosis in a family (among sisters) was defined as the index diagnosis, and we considered all sisters of this woman to be exposed from the date of the index diagnosis in their family. Thus, women were unexposed until one of their sisters was diagnosed with breast cancer, but from the date of this index diagnosis they were considered as exposed until they experienced breast cancer themselves or were censored. Index cases contributed just one record (unexposed) to the data, whereas the at-risk sisters of index cases could contribute two, one unexposed and one exposed. Statistical Methods Absolute Risk of Breast Cancer by Age. We plotted the smoothed hazard of breast cancer by age, adjusted for calendar year, using an algorithm developed by Pawitan ( 10 ) that was modified to account for late entry (ie, entry in the study after birth) and empty bins (ie, age categories with no individuals) and to adjust for linear covariates (eg, calendar time). The algorithm performs a likelihood- based smoothing in a mixed model framework using the Poisson structure of the data. The number of events in each increment of time can be considered to follow a Poisson distribution whose mean is the expected number of events (ie, the product of person-time at risk and instantaneous hazard rate). A smoothed hazard function is constructed from a linear combination of B-splines ( 11 ), where the coefficients can be regarded as random effects in a mixed model ( 12 ). This method enables one to obtain confidence intervals (CIs). The algorithm is written in R and is available from the authors. Relative Risk of Breast Cancer by Age. We compared the incidence of breast cancer in exposed and unexposed sisters using a Poisson model that accommodates more than one timescale. To 722 Articles JNCI Vol. 100, Issue 10 May 21, 2008

3 do so, we split the records into unexposed and exposed time windows, age categories spanning the range covered by the Multi- Generation Register (20 39, 40 49, 50 59, and years), and calendar periods ( , , , , , , , , and ). We then aggregated the records with the same covariate patterns (exposure status, age, calendar time, and family size [ie, number of sisters]), recording the total number of breast cancer events and the total time that each sister spent in each of these intervals. We modeled the number of events ( y i ) in interval i as a Poisson variable: log(y i ) = X i + log( pt i ), where X i represents the vector of covariates in interval i, represents the vector of regression coefficients, and pt i is the total person-time that sisters spent in interval i. We conducted a stratified analysis to examine whether the risk in exposed women was modified by diagnosis of a younger vs older index case ( 45 years vs >45 years), where the cut point was chosen to have sufficient events in the young sisters at risk. To investigate whether the relative risk of breast cancer is different when the woman is approaching or has already passed the age at which her index sister was diagnosed, we split the exposure time of sisters into two periods depending on whether the current age was younger or older than the age of the index sister when she was diagnosed, creating a new dichotomous variable (younger or older). We then used a Poisson model similar to that used before, with age categorized as 25 34, 35 44, 45 54, and years, and an interaction term between exposure and the younger/older variable. Again, we repeated the analysis stratified by age at diagnosis of the index case ( 45 years vs >45 years). Relative Risk of Breast Cancer by Time Since Diagnosis of the Index Case. Finally, we studied how the relative risk changed with time from the first breast cancer diagnosis among the sisters in a family, adjusting for age, calendar time, and family size (number of sisters). The number of events was modeled as Poisson with the following covariates: time from exposure in 5-year intervals (reference category is the unexposed), calendar time (in 5-year intervals), age (in 5-year intervals), and family size. We repeated this analysis stratifying by the current age of the at-risk sisters. To assess the potential underestimation of standard errors due to correlation between sisters in the same family, we repeated our analyses restricted to the two oldest sisters in each family. We also performed analyses restricted to calendar years before 1988 to minimize potential bias from population mammography screening. All data preparation and analyses were performed using SAS 9.1 (SAS Institute, Cary, NC), and estimates of the parameter and its 95% confidence intervals were obtained using PROC GENMOD. All of the figures were produced with R ( www. r- project.org ). Results We followed sisters from 1958 until they attained the age of 70 years, and among them we identified (0.95%) index cases of breast cancer (ie, the first registered case among the sisters in the family) who had sisters, with of these at-risk sisters having follow-up time after the diagnosis of the index sister. Among the women exposed (ie, with an affected sister), 714 (3.02%) developed breast cancer ( Table 1 ). Most (92%) of the women analyzed had two or fewer sisters. The number of exposed sisters was usually somewhat less than the total number of sisters for whom there was an index case because some of these women were censored before the index sister s diagnosis. Absolute Risk of Breast Cancer by Age We derived the smoothed hazard function adjusted for calendar year for breast cancer at ages years in all sisters of breast cancer cases and in unexposed sisters ( Figure 1 ). The widening confidence intervals with age reflect the relatively young age of the cohort: approximately 76% of the sisters were younger than 50 years at the end of follow-up. Sisters of breast cancer patients had higher breast cancer incidence than unexposed sisters at all ages: at age 40 years the rate of breast cancer in unexposed sisters was 5.94 per person-years (95% CI = 5.70 to 6.18) whereas in exposed sisters the rate was per person-years (95% CI = to 24.40); at age 60 years the absolute rate in unexposed sisters was Table 1. Descriptive statistics of the families studied and of exposed families, according to family size (number of sisters in the family) Family size No. of families All families Total No. of sisters Exposed families No. of breast cancers (%) No. of families No. of sisters No. of breast cancers (%) (0.88) (3.19) (1.04) (3.02) (1.28) (3.01) (1.45) (2.30) (1.59) (2.43) (1.64) (3.7) (1.19) (1.1) (1.46) (0.0) (0.91) (0.0) (0.00) (0.00) Total (0.95) (3.02) jnci.oxfordjournals.org JNCI Articles 723

4 Figure 1. Breast cancer incidence (rate per person-year with 95% confidence intervals) in sisters of breast cancer cases (exposed) and in all unexposed sisters as a function of age and adjusted for calendar time per person-years (95% CI = to 30.31), compared with per person-years (95% CI = to 67.08) in exposed sisters. Relative Risk of Breast Cancer by Age The overall incidence of breast cancer in sisters of case subjects was more than double the incidence in the unexposed sisters ( Table 2 ). The increased risk associated with exposure (ie, having a sister diagnosed with breast cancer) was greatest for women aged years (incidence rate ratio [IRR] = 6.64, 95% CI = 4.66 to 9.48). The relative risk was approximately 2.5 for sisters in their forties, and the risk then decreased further in older women so that there was an increased risk of approximately twofold in women older than 50 years. To gain some insight into possible differences in risks associated with having a sister diagnosed with breast cancer at a younger or older age, we repeated the analysis after stratifying by the age at which the index case was diagnosed ( 45 and >45 years, Table 2 ). We found no evidence of a statistically significant difference in the risk for sisters of younger and older index cases ( 2 = 0.15, P =.70 from Wald test). All risk estimates according to age were adjusted for calendar time and family size. The calendar time was statistically significant in all analyses, as expected from Figure 1, and failure to adjust resulted in overestimation of familial risk. The relative risk of breast cancer had a similar pattern in sisters who were approaching and sisters who had already attained the age at which their index sister was diagnosed ( Figure 2 ). The incidence rate ratio of breast cancer in exposed sisters was highest at age years, whether they were younger (IRR = 7.6, 95% CI = 3.6 to 15.9) or older (IRR = 8.3, 95% CI = 2.7 to 25.9) than the age at diagnosis of the index case. After age 35 years, the relative risk was approximately 2.5, whether the woman was younger or older than the age of the index case at the time of diagnosis. We repeated these analyses stratified by the age at which the index case was diagnosed and the pattern was similar (data not shown). In analyses restricted to calendar years before nationwide population mammography screening in Sweden, the pattern of risk with age (data not shown) was similar to that reported in Table 2. Restricting our cohort to the two oldest sisters for each family, the 555 exposed women had very similar IRRs and confidence intervals (age 20 39: IRR = 6.05, 95% CI = 3.64 to 10.05; age 40 49: IRR = 2.64, 95% CI = 2.22 to 3.15; age 50 59: IRR = 2.16, 95% CI = 1.91 to 2.44; age 60 69: IRR = 2.15, 95% CI = 1.80 to 2.57), and all the associations remained statistically significant (data not shown), except for one stratum with very limited data (sisters aged years with an index case diagnosed after age 45 years), for which only one event remained in the restricted dataset. Relative Risk of Breast Cancer by Time Since Diagnosis of the Index Case The overall relative risk of breast cancer in exposed sisters compared with unexposed was constant over time for 20 years, with the incidence rate ratios ranging from 2.09 to 2.16 ( Table 3 ). To examine how the risk for exposed women depends on time since the index diagnosis while taking into consideration age effects, we studied the relative risks by time in analyses stratified by current age of at-risk sisters ( Table 3 ). For women who were older than 40 years and had a sister diagnosed with breast cancer, the increased risk compared with that in unexposed women was approximately constant over time. Women who were younger (<40 years) had the highest relative risk for breast cancer, and there was no clear trend in the incidence rate ratio over time for these women, but the estimates were based on small numbers. Table 2. Number of breast cancer events (in unexposed and exposed sisters) and age-specific incidence rate ratio estimates for the sisters at risk, stratified by age at diagnosis of the index case* Unexposed Exposed Exposed to an index case diagnosed at age 45 years Exposed to an index case diagnosed at age >45 years Age (y) Events IRR Events IRR (95% CI) Events IRR (95% CI) Events IRR (95% CI) (4.7 to 9.5) (4.6 to 9.9) 4 6 (2 to 20) (2.19 to 2.92) (1.80 to 2.70) (2.40 to 3.55) (1.86 to 2.32) (1.80 to 2.60) (1.78 to 2.32) (1.81 to 2.56) (1.3 to 2.9) (1.82 to 2.67) * Estimates obtained from Poisson regression models with adjustment for calendar year and family size. IRR = incidence rate ratio, CI = confidence interval. Age of the sister at risk. 724 Articles JNCI Vol. 100, Issue 10 May 21, 2008

5 IRR (exposed versus not exposed) Discussion sisters before they attain the age at diagnosis of the index sisters after they have passed the age at diagnosis of the index age Figure 2. Incidence rate ratio (IRR) of breast cancer and 95% confidence intervals by age for sisters younger and older than the age at diagnosis of the index case. Estimates were obtained from Poisson regression models adjusted for calendar year and family size. Although there has been considerable effort to estimate the dependence of the risk of familial breast cancer on age ( 2 5, 13, 14 ), the focus of these efforts was more on the age of the breast cancer patients than on the age of their relatives ( 4, 15 ). This emphasis is understandable because young age at the time of diagnosis of breast cancer is associated with the presence of BRCA1 and BRCA2 mutations ( 14, 16, 17 ). However, the risk of breast cancer in the general female population and in relatives of breast cancer patients depends strongly on age ( 2, 13, 14 ). Furthermore, there is a third timescale that may need to be considered, that is, the time that has elapsed since the index diagnosis in the family. We are unaware of any published research that has attempted to determine the dependence of the familial breast cancer risk on these different timescales. Our work offers a better understanding of the timing of familial breast cancer, which is important for providing a more clear and focused counseling message to sisters of breast cancer patients and could also help in the planning of screening programs ( 18 ), which have been shown to be beneficial for women younger than 50 years with a family history of breast cancer ( 19 ). The age-specific incidence of breast cancer in our cohort agreed with the Swedish population rates ( 20, 21 ), although the overall incidence was low (approximately 1%) due to limited follow-up. We observed a higher incidence of breast cancer in sisters of case subjects than in women from unaffected families ( Figure 1 ), similar to results obtained by many studies ( 4, 13, 14, 16, 22 ). The inflection in risk around the time of menopause ( 6, 7 ) known as Clemmesen s Hook ( 23 ) is clearly visible in the unexposed sisters ( Figure 1 ). The absolute risk in affected and unaffected families increased steadily with age, and there was a statistically significant difference in the risks in these two populations at all ages. In agreement with previous studies ( 2, 4 ), we found a very high risk for women who were young (20 39 years) when the index Table 3. Number of breast cancer events (in exposed and unexposed sisters) and incidence rate ratio estimates by current age of the at-risk sister and time since diagnosis of the index case * Current age of the sister at risk (y) Time since diagnosis of the index case (y) Number of events IRR (95% CI) All ages (20 69) Unexposed Referent (1.91 to 2.39) (1.88 to 2.47) (1.73 to 2.52) (1.63 to 2.78) Unexposed 2564 Referent (3.7 to 9.5) (5.2 to 17.0) (1 to 14) Unexposed 6392 Referent (2.11 to 3.11) (1.97 to 3.35) (1.7 to 3.7) (1 to 4) Unexposed 5982 Referent (1.75 to 2.43) (1.66 to 2.48) (1.76 to 2.95) (1.7 to 3.6) Unexposed 1547 Referent (1.4 to 2.5) (1.9 to 3.3) (1.7 to 3.6) (1.3 to 3.8) * Estimates obtained from Poisson regression models adjusted for calendar year and family size. IRR = incidence rate ratio, CI = confidence interval. All sisters aged years followed for a maximum exposure time of 20 years. case was diagnosed in a sister relative to the risk in women with unaffected sisters ( Table 2 ). For women older than 50, the increased relative risk (relative to women with no affected sisters) was approximately 2; for women aged years, the relative risk was slightly higher than 2. The high risk in young women is expected because in families where there is a breast cancer there will be a higher prevalence of BRCA1 and/or BRCA2 mutations than in the general population and thus an increased risk of cancer, especially at younger ages ( 24 ). However, this risk was modified only slightly by the age of the index case ( 15 ): comparing families with index cases of 45 years and younger with families where the index cases were older than 45 years, the relative risks in sisters aged years were approximately 7.0 and 6.0, respectively. This similarity contrasts with many studies that have reported a higher risk in relatives of younger women diagnosed with breast cancer, but these studies used case control designs ( 14 ) or analyzed cohorts of relatives of patients that did not distinguish the time order of the diagnoses in the family ( 15 ). Only a few studies have attempted to study the interaction between the age of the breast cancer patient and the age of her relative, with inconsistent findings ( 14 ). To examine whether the observed high risk in young sisters of affected women could be confounded by screening behavior, we repeated the analysis for the time periods before the introduction of screening in Sweden. The pattern of risk with age was similar to jnci.oxfordjournals.org JNCI Articles 725

6 that reported in Table 2, providing no evidence of preferential screening of young sisters. Exposed sisters showed similar breast cancer risks at ages younger and older than the age at diagnosis of the index case ( Figure 2 ). These results suggest that there is not a predetermined age at which members of a family enter a high-risk state, as proposed by Peto and Mack ( 6 ). In that paper, the authors claimed that the absolute breast cancer risk increases to a high constant level at an age that is specific to each family. Although our work focused on relative and not absolute risk, the results suggest that there is no change in the risk profile of a woman as she approaches and passes the age at which the index sister was diagnosed in her family. Recent work in which breast cancer patients were tested for BRCA1 and BRCA2 mutations also found no evi - dence of risk depending on age in families of patients with these mutations ( 15 ). When women of all ages were analyzed together, the incidence rate ratio of breast cancer appeared to be constant with time after diagnosis of the index case ( Table 3 ). We found that exposed sisters had approximately double the risk of breast cancer relative to unexposed women for at least 20 years after the index sister was diagnosed in their family. Previous work has shown the familial risk of breast cancer to be higher in the same year as the index diagnosis, suggesting increased surveillance in the family ( 8, 25 ), but the lack of an increased risk in the first 5 years in our data suggests that there is no substantial surveillance bias. Stratification by the age of the at-risk sisters revealed that exposed sisters of all age categories had a constant relative risk of breast cancer over time. Women who were young (less than 40 years) had the highest relative risk for breast cancer (in agreement with Table 2 ), and we could discern no clear trend over time from these analyses, which were based on small numbers. A strength of our study is the availability of the population registers of Sweden, which enabled us to plot the age-specific smoothed incidence rate of breast cancer with narrow confidence intervals for the general population and for sisters. We also developed an algorithm to adjust these hazards for the known in - creasing incidence with calendar time. Our focus on sisters and not mother and daughter pairs is more relevant for studying whether time since index diagnosis is important for counseling because sisters are likely to belong to the same age group. Moreover, by using sisters, we avoided the possible bias due to the different environmental exposure between mothers and daughters because sisters live in more similar calendar periods ( 14, 26 ). Our results may be relevant for other familial relationships because previous studies show that the increased risk associated with having an affected sister is similar to that associated with having an affected mother ( 4, 14 ). Our study did not include cancers diagnosed before 1958 (the start-up year of the Swedish cancer registry), but there was minimal bias due to this truncation: the sisters in our study were all born after 1931, so that in 1958 they were at most 27 years old and thus highly unlikely to have already developed a cancer. A limitation of our study is that we could not study breast cancer in very old women. Because the Swedish Multi-Generation Register started with individuals born in or after 1932 and followup ended in 2001, we could only follow sisters to a maximum age of 70 years. This age span covers times of substantial risk in the life of a woman. However, the apparent flattening of the hazard in exposed sisters older than 60 years may be due to the small sample sizes, reflected in wide confidence intervals ( Figure 1 ). There is also potential bias due to the available register data because some older sisters (born before1932) may not have been included in the analysis. Another limitation is the possible misclassification of exposure because full siblings cannot be identified for many women who died before However, we have shown elsewhere ( 27 ) that there is no bias from this source except where there is a large difference in the mortality of familial and nonfamilial cases. Even if there was evidence of such differential mortality for breast cancer, it would lead to only a slight underestimate of the modest familial risk, and, thus, any bias would have little impact on our conclusions. Our analysis did not model the correlation between breast cancer risk in sisters in the same family so that the inclusion of women from families of three or more sisters could have led to some underestimation of the confidence intervals. Nevertheless, when we repeated all the analyses including only the two oldest sisters for each family, the results were similar. In our analysis, we did not consider important risk factors for breast cancer such as age at first birth or use of hormone replacement therapy. However, we do not expect this decision to have a large impact on our results because a previous study in the same population ( 28 ) showed that adjustment for reproductive factors did not change the estimates of familial risk. Our choice of starting time of exposure (date of diagnosis in a sister) was not based on a biologic hypothesis but was motivated by the aim of providing a counseling message for women who have a family member that was diagnosed with breast cancer. The first diagnosis in a family is indeed the time where women first become aware of their increased risk of breast cancer, and we wished to estimate whether the perceived higher risk from the date of diagnosis of a sister was modified by time. We found no evidence of such effect modification or of a change in risk profile as a woman approaches and passes the age at onset of breast cancer in her affected sister. Thus, the assumption of constant risk with respect to these time axes in current breast cancer prediction models ( 29 ) is reasonable, although our observation of the confounding effect of calendar time suggests that its effect on these predictions is worthy of investigation. In conclusion, we confirmed that familial breast cancer risk is highly dependent on age but appears to be quite constant with time since the index diagnosis. In particular, sisters of women diagnosed with breast cancer still have an increased risk of breast cancer 20 years after diagnosis of the sister, suggesting that women live with the burden of familial breast cancer for their lifetime. This suggests a need for intense screening of sisters in affected families for the rest of their life, independent of the age-related screening recommendations. References 1. Hemminki K, Czene K. Attributable risks of familial cancer from the Family-Cancer Database. Cancer Epidemiol Biomarkers Prev ; 11 ( 12 ): Rawal R, Bertelsen L, Olsen JH. Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer. Eur J Cancer ; 42 ( 17 ): Articles JNCI Vol. 100, Issue 10 May 21, 2008

7 3. Tulinius H, Sigvaldason H, Olafsdóttir G, Tryggvadóttir L, Bjarnadóttir K. Breast cancer incidence and familiality in Iceland during 75 years from 1921 to J Med Genet ; 36 ( 2 ): Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet ; 358 ( 9291 ): Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol ; 131 ( 6 ): Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet ; 26 ( 4 ): Easton D. Breast cancer not just whether but when? Nat Genet ; 26 ( 4 ): Bermejo JL, Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst ; 97 ( 21 ): Statistic Sweden. 2004:7 Multi-Generation Register A description of contents and quality Multi-Generation register. Örebro, Sweden : STATISTISKA CENTRALBYRÅN; BE/OV9999/2003A01/OV9999_2003A01_BR_BE96ST0407.pdf. [Last accessed: April 16, 2008.] 10. Pawitan Y. In All Likelihood: Statistical Modelling and Inference Using Likelihood. Oxford, UK : Oxford University Press ; 2001 : De Boor C. A Practical Guide to Splines. New York, NY : Springer-Verlag ; 1978 : Lee Y, Nelder J, Pawitan Y. Generalized Linear Models with Random Effects: Unified Analysis via H-likelihood. London, UK : Chapman and Hall ; 2006 : Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med ; 84 ( 1 ): Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer ; 71 ( 5 ): Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev ; 15 ( 2 ): Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst ; 95 ( 6 ): Suthers GK. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation. ANZ J Surg ; 77 ( 5 ): Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med ; 357 ( 2 ): Maurice A, Evans DG, Shenton A, et al. Screening younger women with a family history of breast cancer does early detection improve outcome?. Eur J Cancer ; 42 ( 10 ): The National Board of Health and Welfare. [Last accessed: April 16, 2008.] 21. Hemminki K, Li X, Plna K, Granström C, Vaittinen P. The nation-wide Swedish family-cancer database updated structure and familial rates. Acta Oncol ; 40 ( 6 ): Hemminki K, Granström C, Czene K. Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden. Int J Cancer ; 100 ( 2 ): Hakama M. The peculiar age specific incidence curve for cancer of the breast Clemmesen s hook. Acta Pathol Microbiol Scand ; 75 ( 3 ): Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA ; 299 ( 2 ): Hemminki K, Bermejo JL. Effects of screening for breast cancer on its ageincidence relationships and familial risk. Int J Cancer ; 117 ( 1 ): Paltiel O, Friedlander Y, Deutsch L, et al. The interval between cancer diagnosis among mothers and offspring in a population-based cohort. Fam Cancer ; 6 ( 1 ): Leu M, Czene K, Reilly M. The impact of truncation and missing family links in population-based registers on familial risk estimates. Am J Epidemiol ; 166 ( 12 ): Hemminki K, Granström C. Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res Treat ; 82 ( 1 ): Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam Cancer ; 1 ( 3 4 ): Funding Swedish Cancer Society (Cancerfonden, registration number , contracts and ). Notes The funder had no role in the design of this study, the data analysis, data interpretation, the writing of the report, or the authors decision to submit the paper for publication. We thank Agus Salim for help with the computer code for smoothing adjusted hazard ratios. Manuscript received November 9, 2007 ; revised March 17, 2008 ; accepted April 7, jnci.oxfordjournals.org JNCI Articles 727

Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients

Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

More information

A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients

A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients British Journal of Cancer (2002) 86, 718 722 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com A follow-up study of breast and other cancers in families of an unselected series of breast cancer

More information

breast cancer; relative risk; risk factor; standard deviation; strength of association

breast cancer; relative risk; risk factor; standard deviation; strength of association American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:

More information

Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates

Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates DOI: 10.1093/jnci/djq265 Advance Access publication on August 19, 2010. The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.

More information

A Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers

A Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY

More information

The assessment of genetic risk of breast cancer: a set of GP guidelines

The assessment of genetic risk of breast cancer: a set of GP guidelines Family Practice Vol. 16, No. 1 Oxford University Press 1999 Printed in Great Britain The assessment of genetic risk of breast cancer: a set of GP guidelines GH de Bock, a,b TPM Vliet Vlieland, b GCHA Hageman,

More information

Familial risk of early and late onset cancer: nationwide prospective cohort study. Kharazmi, Elham; Fallah, Mahdi; Sundquist, Kristina; Hemminki, Kari

Familial risk of early and late onset cancer: nationwide prospective cohort study. Kharazmi, Elham; Fallah, Mahdi; Sundquist, Kristina; Hemminki, Kari Familial risk of early and late onset cancer: nationwide prospective cohort study Kharazmi, Elham; Fallah, Mahdi; Sundquist, Kristina; Hemminki, Kari Published in: B M J: British Medical Journal DOI:.36/bmj.e876

More information

Epidemiology of breast cancer in families in Iceland

Epidemiology of breast cancer in families in Iceland 158 18 Med Genet 1992; 29: 158-164 Icelandic Cancer Registry, Icelandic Cancer Society, PO Box 5420, Sk6garhlid 8, 125 Reykiavik, Iceland. H Tulinius H Sigvaldason G Olafsd6ttir L Tryggvad6ttir Department

More information

Presymptomatic diagnosis of hereditary breast cancer

Presymptomatic diagnosis of hereditary breast cancer Presymptomatic diagnosis of hereditary breast cancer Published Oct 5, 2000 Version 1 Findings by SBU Alert The discovery that mutations in two specific genes increase the risk for breast cancer and ovarian

More information

Challenges in design and analysis of large register-based epidemiological studies

Challenges in design and analysis of large register-based epidemiological studies FMS/DSBS autumn meeting 2014 Challenges in design and analysis of large register-based epidemiological studies Caroline Weibull & Anna Johansson Department of Medical Epidemiology and Biostatistics (MEB)

More information

Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results

Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results Original article Annals of Oncology 15: 350 353, 2004 DOI: 10.1093/annonc/mdh072 Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results H. M. Verkooijen

More information

Evidence Based Medicine

Evidence Based Medicine Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed

More information

Relation of Height and Body Mass Index to Renal Cell Carcinoma in Two Million Norwegian Men and Women

Relation of Height and Body Mass Index to Renal Cell Carcinoma in Two Million Norwegian Men and Women American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 12 Printed in U.S.A. DOI: 10.1093/aje/kwh345 Relation of Height

More information

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers Hereditary Cancer in Clinical Practice 2007; 5(2) pp. 67-71 No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers Pål Møller 1, Lovise Mºhle 1, Neal Clark 1, Jaran Apold 2 1 Section

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.

More information

ELIMINATING BIAS IN CANCER RISK ESTIMATES A SIMULATION STUDY

ELIMINATING BIAS IN CANCER RISK ESTIMATES A SIMULATION STUDY ELIMINATING BIAS IN CANCER RISK ESTIMATES A SIMULATION STUDY by SARADHA RAJAMANI A Project submitted to the faculty of The University of Utah in partial fulfillment of the requirements for the degree of

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.

More information

Modelling cancer risk predictions:clinical practice perspective.

Modelling cancer risk predictions:clinical practice perspective. Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult

More information

Childhood Cancer Survivor Study Analysis Concept Proposal

Childhood Cancer Survivor Study Analysis Concept Proposal Title: Multiple Subsequent Neoplasms Working Group and Investigators: Childhood Cancer Survivor Study Analysis Concept Proposal This proposed publication will be within the Second Malignancy Working Group

More information

Updates in Cancer Genetics & Genomics

Updates in Cancer Genetics & Genomics Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

Assessment of lead-time bias in estimates of relative survival for breast cancer

Assessment of lead-time bias in estimates of relative survival for breast cancer Assessment of lead-time bias in estimates of relative survival for breast cancer Therese M-L Andersson a,, Mark J Rutherford b, Keith Humphreys a a Department of Medical Epidemiology and Biostatistics,

More information

Parental antibiotics and childhood asthma : a population-based study. Örtqvist, A.K.; Lundholma, C.; Fang, F.; Fall, T.; Almqvist, C.

Parental antibiotics and childhood asthma : a population-based study. Örtqvist, A.K.; Lundholma, C.; Fang, F.; Fall, T.; Almqvist, C. This is an author produced version of a paper accepted by Journal of Allergy and Clinical Immunology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal

More information

HRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years

HRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years HRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years Frank A. Firgaira, Ram Seshadri, Christopher R. E. McEvoy, Gillian S. Dite, Graham G. Giles, Margaret R. E.

More information

Finland and Sweden and UK GP-HOSP datasets

Finland and Sweden and UK GP-HOSP datasets Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry

More information

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which

More information

How research based on Swedish registries improve health: an international perspective? Hans-Olov Adami

How research based on Swedish registries improve health: an international perspective? Hans-Olov Adami How research based on Swedish registries improve health: an international perspective? Hans-Olov Adami Department of Epidemiology Harvard School of Public Health Department of Medical Epidemiology and

More information

The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence

The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence pp. 186-192 The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence Kari Hemminki 1,2, Charlotta Granström 2, Jan Sundquist 2, Justo

More information

Trends in the Lifetime Risk of Developing Cancer in Ontario, Canada

Trends in the Lifetime Risk of Developing Cancer in Ontario, Canada Trends in the Lifetime Risk of Developing Cancer in Ontario, Canada Huan Jiang 1,2, Prithwish De 1, Xiaoxiao Wang 2 1 Surveillance and Cancer Registry, Analytic and Informatics, Cancer Care Ontario 2 Dalla

More information

JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T

JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 25 NUMBER 11 APRIL 1 27 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Meta-Analysis of BRCA1 and BRCA2 Penetrance Sining Chen and Giovanni Parmigiani From the Departments of Environmental

More information

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,

More information

Biostatistics II

Biostatistics II Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,

More information

FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN

FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN Int. J. Cancer: 94, 444 448 (2001) 2001 Wiley-Liss, Inc. FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN Kari HEMMINKI* and Xinjun LI Department of Biosciences

More information

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women

More information

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia

More information

Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy

Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy Kelly A. Metcalfe, Steven A. Narod Background: Prophylactic bilateral mastectomy is a preventive option for

More information

Advice about familial aspects of breast cancer and epithelial ovarian cancer

Advice about familial aspects of breast cancer and epithelial ovarian cancer Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals

More information

Life expectancy in the United States continues to lengthen.

Life expectancy in the United States continues to lengthen. Reduced Mammographic Screening May Explain Declines in Breast Carcinoma in Older Women Robert M. Kaplan, PhD and Sidney L. Saltzstein, MD, MPH wz OBJECTIVES: To examine whether declines in breast cancer

More information

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161 Ann Rheum Dis 2017;76:1642 1647. doi:10.1136/annrheumdis-2016-211066 Lin, Wan-Ting 2018/05/161 Introduction We and others have previously demonstrated an increased risk of acute coronary syndrome (ACS)

More information

Reliability of Reported Age at Menopause

Reliability of Reported Age at Menopause American Journal of Epidemiology Copyright 1997 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 146, No. 9 Printed in U.S.A Reliability of Reported Age at Menopause

More information

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme British Journal of Cancer (2002) 87, 65 69 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

More information

Subjects and Methods. Results

Subjects and Methods. Results CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:840 845 ORIGINAL ARTICLES Familial Risk for Esophageal Cancer: An Updated Epidemiologic Study From Sweden JIANGUANG JI* and KARI HEMMINKI*, *Department of

More information

INTRODUCTION BREAST CANCER CARE

INTRODUCTION BREAST CANCER CARE INTRODUCTION Breast Cancer Care welcomes the HFEA s consultation on embryo selection for inherited cancer. This is an extremely important and complex issue. Because of this, Breast Cancer Care has encouraged

More information

Treatment issues for women with BRCA germline mutation

Treatment issues for women with BRCA germline mutation Treatment issues for women with BRCA germline mutation Overview Fertility and reproductive lifespan The impact of reproductive life on breast and ovarian cancer risk Screening recommendations during pregnancy

More information

BIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

BIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA BIOSTATISTICAL METHODS AND RESEARCH DESIGNS Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA Keywords: Case-control study, Cohort study, Cross-Sectional Study, Generalized

More information

Changes in Number of Cigarettes Smoked per Day: Cross-Sectional and Birth Cohort Analyses Using NHIS

Changes in Number of Cigarettes Smoked per Day: Cross-Sectional and Birth Cohort Analyses Using NHIS Changes in Number of Cigarettes Smoked per Day: Cross-Sectional and Birth Cohort Analyses Using NHIS David M. Burns, Jacqueline M. Major, Thomas G. Shanks INTRODUCTION Smoking norms and behaviors have

More information

Landmarking, immortal time bias and. Dynamic prediction

Landmarking, immortal time bias and. Dynamic prediction Landmarking and immortal time bias Landmarking and dynamic prediction Discussion Landmarking, immortal time bias and dynamic prediction Department of Medical Statistics and Bioinformatics Leiden University

More information

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:

More information

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes.

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Wu, J. W., Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S. Journal of Clinical

More information

Measuring and predicting cancer incidence, prevalence and survival in Finland

Measuring and predicting cancer incidence, prevalence and survival in Finland Measuring and predicting cancer incidence, prevalence and survival in Finland Timo Hakulinen and Karri Seppä Finnish Cancer Registry- the Institute for Statistical and Epidemiological Cancer Research ABSTRACT

More information

Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology

Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology Sylvia Richardson 1 sylvia.richardson@imperial.co.uk Joint work with: Alexina Mason 1, Lawrence

More information

STUDY. Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin

STUDY. Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin Kari Hemminki, MD, PhD; Chuanhui Dong, MD, PhD STUDY Objectives: To compare cancer risks after in situ and invasive squamous

More information

Estimating and modelling relative survival

Estimating and modelling relative survival Estimating and modelling relative survival Paul W. Dickman Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden paul.dickman@ki.se Regstat 2009 Workshop on Statistical

More information

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation

More information

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol Krishnan et al. BMC Cancer (2017) 17:859 DOI 10.1186/s12885-017-3871-7 RESEARCH ARTICLE Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol study Open Access Kavitha

More information

Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since. By Dawna Gilchrist, MD, FRCPC, FCCMG

Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since. By Dawna Gilchrist, MD, FRCPC, FCCMG By Dawna Gilchrist, MD, FRCPC, FCCMG Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since the discovery of the genes BRCA 1 and 2 in the early 1990s, genetic counselling and testing

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Germline Genetic Testing for Breast Cancer Risk

Germline Genetic Testing for Breast Cancer Risk Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)

More information

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,

More information

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study EUROCARE-5 on-line database Data and methods Extract from Cancer survival in Europe 1999 2007 by country and age: results of EUROCARE-5 a population-based study De Angelis R, Sant M, Coleman MP, Francisci

More information

Rates and patterns of participation in cardiac rehabilitation in Victoria

Rates and patterns of participation in cardiac rehabilitation in Victoria Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human

More information

DRAFT. No. of cases/ deaths. categories. Number of X-ray exposures (for UK & Ireland only ever vs never)

DRAFT. No. of cases/ deaths. categories. Number of X-ray exposures (for UK & Ireland only ever vs never) Table 2.1. Cohort studies of X-ray and Andrieu et al. (2006) Europe & Canada Carr et al. (2002) US cohort X- rays for treatment of peptic ulcers 1601 female BRCA1 + BRCA2 carriers, aged 18+; disease ascertainment

More information

Breast Cancer After Treatment of Hodgkin's Disease.

Breast Cancer After Treatment of Hodgkin's Disease. Breast Cancer After Treatment of Hodgkin's Disease. Hancock SL, Tucker MA, Hoppe R Journal of the National Cancer Institute 85(1):25-31, 1993 Introduction The risks of second malignancy are increased in

More information

Swedish Initiative for Research on Microdata in the Social And Medical Sciences. What is SIMSAM? Anna Holmström

Swedish Initiative for Research on Microdata in the Social And Medical Sciences. What is SIMSAM? Anna Holmström Swedish Initiative for Research on Microdata in the Social And Medical Sciences What is SIMSAM? Anna Holmström Ph.D., SIMSAM Network Coordinator Dept. of Clinical Neuroscience Insurance Medicine Karolinska

More information

Cancer in the Northern Territory :

Cancer in the Northern Territory : Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have

More information

article MATERIALS AND METHODS

article MATERIALS AND METHODS September 2006 Vol. 8 No. 9 article Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention Scott D. Ramsey, MD, PhD 1,2, Paula Yoon, ScD,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170(21):1909-1917. eappendix.

More information

On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance

On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance Colin B. Begg Background: Estimating the lifetime risk associated with (i.e., the penetrance of) genetic

More information

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status JNCI Journal of the National Cancer Institute Advance Access published July 9, 2009 ARTICLE Second Primary Breast Cancer Occurrence According to Hormone Receptor Status Allison W. Kurian, Laura A. McClure,

More information

Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer

Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer Kaylene J. Ready, MS 1, Kristen J. Vogel, MS 2, Deann P. Atchley, PhD 1, Kristine R. Broglio, MS 1, Kimberly K. Solomon, MBA 1, Christopher

More information

The Statistical Analysis of Failure Time Data

The Statistical Analysis of Failure Time Data The Statistical Analysis of Failure Time Data Second Edition JOHN D. KALBFLEISCH ROSS L. PRENTICE iwiley- 'INTERSCIENCE A JOHN WILEY & SONS, INC., PUBLICATION Contents Preface xi 1. Introduction 1 1.1

More information

Childhood Vaccination and Type 1 Diabetes

Childhood Vaccination and Type 1 Diabetes The new england journal of medicine original article Childhood Vaccination and Type 1 Diabetes Anders Hviid, M.Sc., Michael Stellfeld, M.D., Jan Wohlfahrt, M.Sc., and Mads Melbye, M.D., Ph.D. abstract

More information

RESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access

RESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink

More information

I have ovarian cancer

I have ovarian cancer I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (NHS England only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and

More information

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer

More information

Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy

Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy doi: 10.1054/ bjoc.2001.1868, available online at http://www.idealibrary.com on http://www.bjcancer.com Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation

More information

Individual Participant Data (IPD) Meta-analysis of prediction modelling studies

Individual Participant Data (IPD) Meta-analysis of prediction modelling studies Individual Participant Data (IPD) Meta-analysis of prediction modelling studies Thomas Debray, PhD Julius Center for Health Sciences and Primary Care Utrecht, The Netherlands March 7, 2016 Prediction

More information

BRCA genes and inherited breast and ovarian cancer. Information for patients

BRCA genes and inherited breast and ovarian cancer. Information for patients BRCA genes and inherited breast and ovarian cancer Information for patients This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could be

More information

Epidemiology of Ovarian Cancer

Epidemiology of Ovarian Cancer 1 Epidemiology of Ovarian Cancer Karim Elmasry and Simon A. Gayther Translational Research Labs, Windeyer Institute, University College London, UK. Introduction Primary carcinoma of the ovary is the fourth

More information

Cancer and pharmacoepidemiology in Finland. Information sources and research possibilities

Cancer and pharmacoepidemiology in Finland. Information sources and research possibilities Cancer and pharmacoepidemiology in Finland Information sources and research possibilities What I will talk about Register-based data sources available in Finland Register linkage method Available background

More information

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime

More information

Prediction Model For Risk Of Breast Cancer Considering Interaction Between The Risk Factors

Prediction Model For Risk Of Breast Cancer Considering Interaction Between The Risk Factors INTERNATIONAL JOURNAL OF SCIENTIFIC & TECHNOLOGY RESEARCH VOLUME, ISSUE 0, SEPTEMBER 01 ISSN 81 Prediction Model For Risk Of Breast Cancer Considering Interaction Between The Risk Factors Nabila Al Balushi

More information

When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival

When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival COMMENTARY When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival Katherine S. Panageas, Leah Ben-Porat, Maura N. Dickler, Paul B. Chapman, Deborah Schrag Progression-free

More information

Metabolic factors and risk of prostate, kidney, and bladder cancer. Christel Häggström

Metabolic factors and risk of prostate, kidney, and bladder cancer. Christel Häggström Metabolic factors and risk of prostate, kidney, and bladder cancer Christel Häggström Department of Surgical and Perioperative Sciences, Urology and Andrology Umeå University, 2013 Metabolic factors and

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women s Health Initiative randomized

More information

12 CANCER Epidemiology Methodological considerations

12 CANCER Epidemiology Methodological considerations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 12 CANCER 12.1 Epidemiology 12.1.1 Methodological

More information

Title: Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study

Title: Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study Author's response to reviews Title: Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study Authors: Inger J Bakken (inger.bakken@sintef.no)

More information

11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy?

11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy? updated 2012 Management of epilepsy in women of child bearing age Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal

More information

Topics. BRCA 1 and BRCA 2 Mutations. Breast cancer BRCA1 / BRCA BRCA 1 und BRCA 2 Mutations and hormonal therapy

Topics. BRCA 1 and BRCA 2 Mutations. Breast cancer BRCA1 / BRCA BRCA 1 und BRCA 2 Mutations and hormonal therapy BRCA 1 and BRCA 2 Mutations Recommendations for Contraception PD G.Merki USZ Breast Cancer risk Topics Breast Cancer risk and hormonal Contraception BRCA 1/2 mutations and changes in risk for breast and

More information

Steven Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute

Steven Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute Steven Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute Objectives Develop a systematic way to think about benefits and harms of cancer

More information

IN 1992, Berkel and colleagues reported the results

IN 1992, Berkel and colleagues reported the results Vol. 332 No. 23 BREAST IMPLANTS AND BREAST CANCER 1535 BREAST IMPLANTS AND BREAST CANCER REANALYSIS OF A LINKAGE STUDY Abstract Background. In 1992, Berkel and colleagues reported in the Journal the results

More information

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation. Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification

More information

Marital Status, Education, and Income in Relation to the Risk of Esophageal and Gastric Cancer by Histological Type and Site

Marital Status, Education, and Income in Relation to the Risk of Esophageal and Gastric Cancer by Histological Type and Site Marital Status, Education, and in Relation to the Risk of and Gastric Cancer by Histological Type and Site Jesper Lagergren, MD, PhD 1,2 ; Gunnar Andersson, PhD 3 ; Mats Talb ack, PhD 4 ; Sven Drefahl,

More information

Statistical Analysis of Biomarker Data

Statistical Analysis of Biomarker Data Statistical Analysis of Biomarker Data Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, CO NCIC Clinical Trials Group New Investigator Clinical Trials Course

More information

Report on Cancer Statistics in Alberta. Melanoma of the Skin

Report on Cancer Statistics in Alberta. Melanoma of the Skin Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of

More information

Using Cancer Registry Data for Post Marketing Surveillance of Rare Cancers

Using Cancer Registry Data for Post Marketing Surveillance of Rare Cancers Using Cancer Registry Data for Post Marketing Surveillance of Rare Cancers Hannah K Weir, PhD Epidemiology and Applied Research Branch Division of Cancer Prevention and Control CDC NAACCR Annual Conference

More information

ORIGINAL ARTICLE. Family History of Psychiatric Illness as a Risk Factor for Schizoaffective Disorder

ORIGINAL ARTICLE. Family History of Psychiatric Illness as a Risk Factor for Schizoaffective Disorder ORIGINAL ARTICLE Family History of Psychiatric Illness as a Risk Factor for Schizoaffective Disorder A Danish Register-Based Cohort Study Thomas Munk Laursen, MSc; Rodrigo Labouriau, PhD; Rasmus W. Licht,

More information

Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis

Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis DOI:10.1093/jnci/dju091 First published online May 14, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. Review

More information

Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy?

Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy? Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy? Sam Abbott Supervisors: Hannah Christensen, Ellen Brooks-Pollock University of Bristol 1 1. Lambert, M. L., Hasker,

More information